Biotech and Pharma Industry News | BioPharma Dive
WEBTen-year survival data show long-term benefit of immunotherapy in melanoma. “It’s a real opportunity to reinforce hope and to start getting comfortable with the word ’cure,” said a leader of the study, which tested Opdivo and Yervoy. BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives.
Two decades and $200 billion: AbbVie’s Humira monopoly nears …
WEBMar 17, 2022 · All told, AbbVie filed about 250 patent applications for Humira in the U.S., 90% of them following the drug's 2002 approval, according to the advocacy group Initiative for Medicines, Access & Knowledge. One hundred and thirty have been granted. The strengthened patent shield has stretched AbbVie's legal monopoly in the U.S. for six years beyond the expiration of Humira's main patent in 2016.
Biotech News - BioPharma Dive
WEB6 days ago · Startup Vicebio banks $100M in bid to make ‘cost-effective’ vaccines. The company’s technology, which enables it to target viral proteins in their “prefusion” shape and skip a manufacturing step, could lead to vaccines that are more potent and easier to produce, said CEO Emmanuel Hanon. By Delilah Alvarado • Sept. 23, 2024.
Meso Scale Discovery (MSD): An immunoassay platform with …
WEBFeb 22, 2022 · ADVANTAGES. Sensitivity, Range and Ease-of-Use: In comparison to a conventional ELISA, MSD has higher sensitivity (LLOD 0.1-1.4 pg/mL) and a larger dynamic detection range (0.1-10 pg/mL).In addition, MSD has an efficient low volume sampling (1-25 μ L) and minimized matrix effect aiding in simultaneous multiplex detection with high precision. . Furthermore, MSD has simpler protocols, reduced ...
Novartis funnels $300M into early biologic drug manufacturing
WEBSep 12, 2022 · Novartis. Novartis will spend $300 million to bolster its development and production capabilities for biologic medicines, which make up an increasing share of its drug pipeline. The Swiss drugmaker will invest $110 million in clinical manufacturing capacity in Mengeš, Slovenia and $60 million in development manufacturing capacity at its ...
In first, FDA approves RNA interference drug from Alnylam
WEBAug 10, 2018 · Approval of Onpattro — OK’d to treat peripheral nerve disease caused by hereditary ATTR amyloidosis — delivers on the promise of RNAi first sketched out in 1998 by scientists Andrew Fire and Craig Mello. But it won’t come cheap: Alnylam plans to sell the drug at an average annual list price of $450,000 per patient. Access now .
Biotech IPOs are the industry’s lifeblood. Track how they’re …
WEBSep 23, 2024 · IPO activity reached a peak in 2021, when more than 100 biotechs priced an initial offering and together raised nearly $15 billion. But that momentum came to a halt as 2021 turned to 2022, and stock prices of newly public companies plummeted amid a sector-wide downturn. The pace of IPOs stalled and, last year, only 19 drugmakers priced initial ...
Lilly wins FDA approval for new kind of diabetes drug
WEBMay 13, 2022 · The Food and Drug Administration on Friday approved Eli Lilly’s diabetes drug Mounjaro, a first-of-its-kind treatment that can help control patients’ blood sugar and, potentially, help them lose weight as well. Mounjaro, also known as tirzepatide, expands Lilly’s diabetes business, which includes insulins as well as other types of therapies.
Lilly, Boehringer diabetes pill wins expanded use in heart failure
WEBFeb 25, 2022 · The Food and Drug Administration approved expanded use of Eli Lilly and Boehringer Ingleheim’s diabetes drug Jardiance, announcing Thursday that the pill can be used in a broader group of heart failure patients. The FDA cleared the drug for sicker patients, those with weaker heart muscles, in August 2021. The …
Biotech M&A has plateaued. Track the deals that are happening …
WEBSep 18, 2024 · Inside the market of emerging biotech. New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously. BioPharma Dive is tracking M&A activity below. The database, which shows drugmaker buyouts that have happened since 2018 and were valued at …